In the article by the American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs published in the August 2008 issue of Arthritis Care & Research (pp. 1058–1073), there were two errors in the text. The first sentence in the third paragraph of the Selective NSAIDs Versus Nonselective NSAIDs section (page 1059) should have read, … followed more than 7,000 patients with both OA and RA over 6–15 months; this trial found a slightly lower dropout rate in patients treated with celecoxib compared with those receiving ibuprofen or diclofenac (12.6% versus 14.8%). Also, the SUCCESS-1 trial dosages in that same paragraph were stated incorrectly. The correct dosages are celecoxib 100 mg twice daily, celecoxib 200 mg twice daily, diclofenac 50 mg twice daily, and naproxen 500 mg twice daily.

We regret the errors.